Table 5 Drug safety assessment of metformin
From: Clinical efficacy of metformin in familial adenomatous polyposis and the effect of intestinal flora
| Â | Test group | Placebo | p value |
|---|---|---|---|
Creatinine (mg/dL) | Â | Â | Â |
At baseline | 72.92 | 67.73 | 0.126 |
At 1Â year | 72.5 | 69.22 | 0.352 |
p value (baseline vs. 1 year) | 0.913 | 0.378 | Â |
Blood urea nitrogen (mg/dL) | Â | Â | Â |
At baseline | 3.39 | 4.92 | 0.02 |
At 1Â year | 3.73 | 5.42 | 0.006 |
p value (baseline vs. 1 year) | 0.229 | 0.575 | Â |
Total cholesterol (mg/dL) | Â | Â | Â |
At baseline | 3.75 | 2.93 | 0.112 |
At 1Â year | 3.74 | 2.62 | 0.023 |
p value (baseline vs. 1 year) | 0.978 | 0.66 | Â |
LDL cholesterol (mg/dL) | Â | Â | Â |
At baseline | 2.06 | 2.26 | 0.768 |
At 1Â year | 2.21 | 2.34 | 0.988 |
p value (baseline vs1 year) | 0.757 | 0.735 | Â |
Aspartate aminotransferase (AST) | Â | Â | Â |
At baseline | 19.6 | 14.85 | 0.045 |
At 1Â year | 17.4 | 15.22 | 0.061 |
p value (baseline vs. 1 year) | 0.377 | 0.886 | Â |
Alanine aminotransferase (ALT) | Â | Â | Â |
At baseline | 33.19 | 15.02 | 0.089 |
At 1Â year | 18.29 | 16.47 | 0.336 |
p value (baseline vs. 1 year) | 0.008 | 0.395 | Â |
HbA1c (%) | Â | Â | Â |
At baseline | 5.53 | 5.45 | 0.494 |
At 1Â year | 5.49 | 5.55 | 0.558 |
p value (baseline vs. 1 year) | 0.665 | 0.412 | Â |
HOMA-IR | Â | Â | Â |
At baseline | 1.18 | 0.97 | 0.528 |
At 1Â year | 1.16 | 0.93 | 0.335 |
p value (baseline vs. 1 year) | 0.968 | 0.826 | Â |
BMI (Kg/m2) | Â | Â | Â |
At baseline | 23.10 | 21.7 | 0.491 |
At 1Â year | 22.16 | 21.57 | 0.745 |
p value (baseline vs. 1 year) | 0.543 | 0.956 | Â |